Table 2. Characteristics of breast cancer treatment after propensity score matching.
*: Significant difference between the two groups.
VEL: vaginal erbium SMOOTH mode laser treatment; VEL+Nd:YAG: VEL and neodymium-doped yttrium-aluminum-garnet laser combination treatment; AIs: aromatase inhibitors
| VEL+Nd:YAG group | VEL group | P-value* | |
| Number of women | 102 | 102 | |
| Stage of breast cancer | |||
| Stage I | 51% | 58% | 0.328 |
| Stage II | 31% | 30% | 0.880 |
| Stage III | 5% | 8% | 0.392 |
| Stage IV | 2% | 0% | 0.157 |
| Stage unknown | 11% | 4% | 0.037 |
| Chemotherapy | |||
| No chemotherapy | 66% | 64% | 0.768 |
| Chemotherapy | 34% | 36% | 0.560 |
| Tamoxifen use | |||
| No tamoxifen | 23% | 32% | 0.156 |
| 0–2 years | 28% | 27% | 0.875 |
| 2–5 years | 20% | 33% | 0.037* |
| 5 + years | 29% | 8% | <0.001* |
| AIs use | |||
| No AI | 47% | 34% | 0.062 |
| 0–2 years | 14% | 27% | 0.023* |
| 2–5 years | 34% | 31% | 0.653 |
| 5 + years | 29% | 8% | <0.001* |